Soraia Azevedo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Soraia Azevedo has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
Filipa Teixeira
Rheumatology Department, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal
5 shared publicationsD. Peixoto
Unidade Local Saude Alto Minho, Rheumatol Dept, Ponte do Lima, Portugal
4 shared publications- Joana Ramos Rodrigues
Serviço de Reumatologia, Unidade Local de Saúde Do Alto Minho, Ponte de Lima, Portugal
4 shared publications D. Santos-Faria
Unidade Local Saude Alto Minho, Rheumatol Dept, Ponte do Lima, Portugal
3 shared publications- Daniela Peixoto
Department of Rheumatology, Unidade Local de Saúde do Alto Minho, Ponte de Lima.
3 shared publications - Daniela Santos-Faria
Unidade Local Saude Alto Minho, Serv Reumatol, Ponte do Lima, Portugal
3 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by Wiley in Rheumatology & Autoimmunity
Clinical predictors of response to methotrexate in patients with rheumatoid arthritis: A systematic review
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation, structural damage, and disability. Methotrexate (MTX) is the first‐line treatment; however, up to one‐third of patients exhibit an inadequate response. This systematic review aimed to identify clinical, serological, genetic, pharmacogenomic, and treatment‐related predictors of MTX response in RA. Methods: A systematic search of PubMed/MEDLINE, Scopus, and the Cochrane Central Register of Controlled Trials (CENTRAL) was conducted for studies published up to May 22, 2024. Randomized controlled trials, prospective cohort studies, and registry‐based studies evaluating predictors of MTX efficacy were included. In total, 87 studies met the eligibility criteria and were included in the review. Predictors were categorized as demographic/clinical, disease‐related, serological/immunological, genetic/pharmacogenomic, treatment‐related, and emerging. Evidence was synthesized narratively, with consideration of methodological quality and consistency. Results: Consistent predictors of favorable MTX response included lower baseline disease activity, better functional status, early MTX initiation, and absence of erosive disease. Male sex, older age, and moderate alcohol consumption were associated with improved outcomes, although these associations may be influenced by treatment‐related and behavioral confounders, whereas smoking and higher body mass index were linked to reduced efficacy. Several inflammatory and cellular biomarkers were associated with MTX response, although individual pharmacogenetic variants showed limited reproducibility. Treatment‐related factors, including subcutaneous administration, rapid dose escalation, glucocorticoid co‐therapy, and folate supplementation, were associated with improved efficacy and tolerability. Emerging proteomic, epigenetic, and metabolomic signatures demonstrated potential for early response prediction. Conclusions: Overall, early disease control and optimized treatment strategies appear to be more reliable predictors of MTX response than isolated demographic or genetic factors. Integration of clinical predictors with emerging molecular biomarkers may support personalized treatment approaches and earlier identification of MTX non‐responders. PROSPERO Registration Number: CRD42023464365.
- 4 August 2026
- Published by Wiley in Rheumatology & Autoimmunity
Open AccessClinical predictors of response to methotrexate in patients with rheumatoid arthritis: A systematic review
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation, structural damage, and disability. Methotrexate (MTX) is the first‐line treatment; however, up to one‐third of patients exhibit an inadequate response. This systematic review aimed to identify clinical, serological, genetic, pharmacogenomic, and treatment‐related predictors of MTX response in RA. Methods: A systematic search of PubMed/MEDLINE, Scopus, and the Cochrane Central Register of Controlled Trials (CENTRAL) was conducted for studies published up to May 22, 2024. Randomized controlled trials, prospective cohort studies, and registry‐based studies evaluating predictors of MTX efficacy were included. In total, 87 studies met the eligibility criteria and were included in the review. Predictors were categorized as demographic/clinical, disease‐related, serological/immunological, genetic/pharmacogenomic, treatment‐related, and emerging. Evidence was synthesized narratively, with consideration of methodological quality and consistency. Results: Consistent predictors of favorable MTX response included lower baseline disease activity, better functional status, early MTX initiation, and absence of erosive disease. Male sex, older age, and moderate alcohol consumption were associated with improved outcomes, although these associations may be influenced by treatment‐related and behavioral confounders, whereas smoking and higher body mass index were linked to reduced efficacy. Several inflammatory and cellular biomarkers were associated with MTX response, although individual pharmacogenetic variants showed limited reproducibility. Treatment‐related factors, including subcutaneous administration, rapid dose escalation, glucocorticoid co‐therapy, and folate supplementation, were associated with improved efficacy and tolerability. Emerging proteomic, epigenetic, and metabolomic signatures demonstrated potential for early response prediction. Conclusions: Overall, early disease control and optimized treatment strategies appear to be more reliable predictors of MTX response than isolated demographic or genetic factors. Integration of clinical predictors with emerging molecular biomarkers may support personalized treatment approaches and earlier identification of MTX non‐responders. PROSPERO Registration Number: CRD42023464365.
- Open Access
- 19 December 2023
- Published by PAGEPress Publications in Reumatismo
- Vol. 75 (4) , 234-236
Lumbosacral pain in a patient with psoriatic arthritis: when the rheumatic disease is innocent
Lumbar pain is a very common symptom that derives from benign musculoskeletal conditions, rheumatic inflammatory diseases, neoplasms, and referred and/or nociplastic pain. A 70-year-old man with psoriatic arthritis presented with early-onset lumbosacral pain without evident red flags. Symptomatic treatment was unhelpful. Radiographic imaging showed subtle signs of a disease that could easily be missed. Magnetic resonance imaging revealed a massive prostatic malignancy with bone (sacral and iliopubic) metastasis. Awareness must be given not to disregard every lumbar pain as part of the preexisting rheumatic inflammatory disease (spondyloarthropathy in this case) or a common muscle/ligament/articular disarrangement. Persistence of pain, albeit not inflam-matory nor sharp in nature, despite adequate treatment might be just as important as an acute red flag and requires proper follow-up.
- 19 December 2023
- Published by PAGEPress Publications in Reumatismo
- Vol. 75 (4) , 234-236
Open AccessLumbosacral pain in a patient with psoriatic arthritis: when the rheumatic disease is innocent
Lumbar pain is a very common symptom that derives from benign musculoskeletal conditions, rheumatic inflammatory diseases, neoplasms, and referred and/or nociplastic pain. A 70-year-old man with psoriatic arthritis presented with early-onset lumbosacral pain without evident red flags. Symptomatic treatment was unhelpful. Radiographic imaging showed subtle signs of a disease that could easily be missed. Magnetic resonance imaging revealed a massive prostatic malignancy with bone (sacral and iliopubic) metastasis. Awareness must be given not to disregard every lumbar pain as part of the preexisting rheumatic inflammatory disease (spondyloarthropathy in this case) or a common muscle/ligament/articular disarrangement. Persistence of pain, albeit not inflam-matory nor sharp in nature, despite adequate treatment might be just as important as an acute red flag and requires proper follow-up.
- 6 October 2022
- Published by Elsevier in Reumatología Clínica (English Edition)
- Vol. 18 (8) , 499-500
Differences and Determinants of Physician's and Patient's Perception in Global Assessment of Rheumatoid Arthritis
- 6 October 2022
- Published by Elsevier in Reumatología Clínica (English Edition)
- Vol. 18 (8) , 499-500
Differences and Determinants of Physician's and Patient's Perception in Global Assessment of Rheumatoid Arthritis
- 1 October 2022
- Published by Elsevier in Reumatología Clínica
- Vol. 18 (8) , 499-500
Differences and Determinants of Physician's and Patient's Perception in Global Assessment of Rheumatoid Arthritis
- 1 October 2022
- Published by Elsevier in Reumatología Clínica
- Vol. 18 (8) , 499-500
Differences and Determinants of Physician's and Patient's Perception in Global Assessment of Rheumatoid Arthritis
- 1 January 2022
- Vol. 1 (1) , 12-20
Predictive factors of relapse after methotrexate discontinuation in juvenile idiopathic arthritis patients with inactive disease
Objective: To identify predictive factors of relapse after discontinuation of Methotrexate (MTX) in Juvenile Idiopathic Arthritis (JIA) patients with inactive disease. Methods: We conducted a prospective multicenter cohort study of patients diagnosed with JIA using real world data from the Portuguese national register database, Reuma.pt. Patients with JIA who have reached JADAS27 inactive disease and discontinued MTX before the age of 18 were evaluated. Results: A total of 1470 patients with JIA were registered in Reuma.pt. Of the 119 bionaive patients who discontinued MTX due to inactive disease, 32.8% have relapsed. Median time of persistence (using the Kaplan-Meier method and log-rank tests) with inactive disease was significantly higher in patients with more than two years of remission before MTX discontinuation and in those who did not use NSAIDs at time of MTX discontinuation. In Cox regression analyses and after adjustment for age at diagnosis, MTX tapering and JIA category, the use of NSAIDs at the time of MTX discontinuation (HR, 1.98 95%CI 1.03-3.82) and remission time of less than two years before suspension (HR, 3.12 95%CI 1.35-7.13) remained associated with relapse. No association was found between JIA category or the regimen of MTX discontinuation and the risk of relapse. Conclusions: In this large cohort we found that the use of NSAIDs at the time of MTX discontinuation was associated with a two times higher likelihood of relapse. In addition, longer duration of remission before MTX withdrawal reduces the chance of relapse in bionaive JIA patients.
- 1 January 2022
- Vol. 1 (1) , 12-20
Predictive factors of relapse after methotrexate discontinuation in juvenile idiopathic arthritis patients with inactive disease
Objective: To identify predictive factors of relapse after discontinuation of Methotrexate (MTX) in Juvenile Idiopathic Arthritis (JIA) patients with inactive disease. Methods: We conducted a prospective multicenter cohort study of patients diagnosed with JIA using real world data from the Portuguese national register database, Reuma.pt. Patients with JIA who have reached JADAS27 inactive disease and discontinued MTX before the age of 18 were evaluated. Results: A total of 1470 patients with JIA were registered in Reuma.pt. Of the 119 bionaive patients who discontinued MTX due to inactive disease, 32.8% have relapsed. Median time of persistence (using the Kaplan-Meier method and log-rank tests) with inactive disease was significantly higher in patients with more than two years of remission before MTX discontinuation and in those who did not use NSAIDs at time of MTX discontinuation. In Cox regression analyses and after adjustment for age at diagnosis, MTX tapering and JIA category, the use of NSAIDs at the time of MTX discontinuation (HR, 1.98 95%CI 1.03-3.82) and remission time of less than two years before suspension (HR, 3.12 95%CI 1.35-7.13) remained associated with relapse. No association was found between JIA category or the regimen of MTX discontinuation and the risk of relapse. Conclusions: In this large cohort we found that the use of NSAIDs at the time of MTX discontinuation was associated with a two times higher likelihood of relapse. In addition, longer duration of remission before MTX withdrawal reduces the chance of relapse in bionaive JIA patients.
- 1 August 2021
- Published by Elsevier in Reumatología Clínica (English Edition)
- Vol. 17 (7) , 422-424
Uncommon causes of nerve compression in the distal forearm
- 1 August 2021
- Published by Elsevier in Reumatología Clínica (English Edition)
- Vol. 17 (7) , 422-424
Uncommon causes of nerve compression in the distal forearm
- 1 August 2021
- Published by Elsevier in Reumatología Clínica
- Vol. 17 (7) , 422-424
Uncommon causes of nerve compression in the distal forearm
- 1 August 2021
- Published by Elsevier in Reumatología Clínica
- Vol. 17 (7) , 422-424
Uncommon causes of nerve compression in the distal forearm
- 1 June 2021
- Published by Elsevier in Reumatología Clínica (English Edition)
- Vol. 17 (6) , 364-365
Remission of Rheumatoid Arthritis and Primary Biliary Cholangitis After Treatment With Tocilizumab
- 1 June 2021
- Published by Elsevier in Reumatología Clínica (English Edition)
- Vol. 17 (6) , 364-365
Remission of Rheumatoid Arthritis and Primary Biliary Cholangitis After Treatment With Tocilizumab
- 1 June 2021
- Published by Elsevier in Reumatología Clínica
- Vol. 17 (6) , 364-365
Remission of Rheumatoid Arthritis and Primary Biliary Cholangitis After Treatment With Tocilizumab
- 1 June 2021
- Published by Elsevier in Reumatología Clínica
- Vol. 17 (6) , 364-365
Remission of Rheumatoid Arthritis and Primary Biliary Cholangitis After Treatment With Tocilizumab
- 1 January 2021
- Published by Sociedad Gallega de Medicina Interna in Galicia Clínica
- Vol. 82 (2) , 75-80
Ancianos: relación entre residencia y estado de salud
- 1 January 2021
- Published by Sociedad Gallega de Medicina Interna in Galicia Clínica
- Vol. 82 (2) , 75-80
Ancianos: relación entre residencia y estado de salud